Why IAPP is tricky to measure
IAPP is a ~3.9 kDa, highly amyloidogenic peptide co-secreted with insulin. Its conformation (monomer ↔ oligomer ↔ fibril), strong surface adsorption, and sequence similarity to related peptides (e.g., insulin, CGRP, calcitonin) create unique pre-analytical and analytical traps. The result: kit-to-kit and lab-to-lab variability that can dwarf biological signals unless workflows are standardized.
Sample-type variability: serum vs plasma vs cell-culture supernatant
Serum
-
Pros: Widely used; large historical datasets.
-
Cons: Clotting releases proteases; variable clot time/temperature can change apparent IAPP. Fibrin remnants and heterophilic antibodies can elevate background.
-
Controls: Fixed clot time (e.g., 30–60 min at RT), immediate centrifugation (e.g., 1500–2000×g, 10–15 min), rapid aliquoting on ice, and storage ≤ −80 °C.
Plasma (EDTA, heparin, citrate)
-
EDTA plasma: Often best for peptides—chelates metalloproteases and tends to give higher recovery.
-
Heparin plasma: May show matrix effects (heparin–protein interactions) and occasionally higher non-specific binding in some antibody pairs.
-
Citrate plasma: Dilution by anticoagulant lowers apparent concentration; requires dilution factor correction.
-
Controls: Pre-dose tubes with protease inhibitor cocktail (serine + metalloprotease + cysteine protease inhibitors). Record anticoagulant type in all reports.
Cell-culture supernatant
-
Pros: Cleaner matrix; controlled media.
-
Cons: Plastic adsorption and in-well aggregation over time (especially at 37 °C). Media components (BSA, phenol red, serum) can alter recovery.
-
Controls: Use low-bind plasticware, add 0.05% Tween-20 or 0.1% BSA as carrier (if compatible with kit), collect at fixed timepoints, clarify by centrifugation, and freeze promptly.
Recommendation: If your project spans multiple cohorts/labs, choose one primary matrix (commonly EDTA plasma) and treat others as secondary. Validate “parallelism” across matrices before pooling data.
Pre-analytical standardization (dominant source of error)
-
Blood draw & processing
-
Use the same tube brand/lot and anticoagulant across study arms.
-
Start a timer at venipuncture; target ≤30 min to freezer at −80 °C.
-
Centrifuge temperature and g-force constant across batches.
-
-
Stabilization & adsorption minimization
-
Add protease inhibitors at draw or immediately post-spin.
-
Use low-bind tubes and tips; pre-rinse pipette tips with sample or diluent.
-
Consider 0.05% Tween-20 (if permitted by kit) to limit wall loss.
-
Avoid glass; IAPP adheres strongly to hydrophobic surfaces.
-
-
Freeze–thaw control
-
Aliquot to single-use volumes; max 1 freeze–thaw for comparability.
-
Document cycle counts in metadata.
-
-
Storage
-
−80 °C long-term; avoid frost-free freezers; include a temperature log.
-
Store standards/calibrators per kit manual; replace upon expiry.
-
Cross-reactivity: insulin, proinsulin, pramlintide, CGRP, calcitonin
Epitope considerations
-
Insulin/proinsulin: Although structurally distinct, polyclonal reagents can show low-level cross-reactivity; insulin is abundant and can bias measurements.
-
Pramlintide (amylin analog): A common confounder in treated samples; verify kit-specific cross-reactivity and report therapy status.
-
CGRP/calcitonin: Sequence homology can cause competitive binding or matrix interference in some formats.
-
Species cross-reactivity: Mouse/rat IAPP differ at key residues; confirm human-specific capture/detection for human studies and vice-versa.
Controls to detect cross-reactivity
-
Spike–recovery in the presence/absence of high insulin (e.g., 100–1000 µU/mL).
-
Competition tests: pre-incubate sample with excess homologous peptide to confirm signal specificity.
-
Parallelism across serial dilutions: non-parallel curves often imply cross-reaction or matrix effects.
ELISA format differences: sensitivity, specificity, and when to use what
| ELISA format | Typical LOD | Specificity driver | Strengths | Cautions |
|---|---|---|---|---|
| Sandwich (mono/mono) | Low pg/mL | Two non-overlapping epitopes | High specificity; good dynamic range | Epitope masking by oligomers/fibrils can reduce signal |
| Sandwich (mono/poly) | Low–mid pg/mL | Capture specificity + broad detection | Robust to minor epitope drift | Slightly higher background vs mono/mono |
| Competitive (antigen competition) | Mid–high pg/mL | Antibody affinity | Better for small peptides & high analyte | Narrow dynamic range; matrix-dependent |
| Oligomer-preferring assays | Assay-dependent | Conformation-specific Abs | Detects toxic oligomers | Calibrator availability and stability issues |
Key choices
-
Total IAPP: prefer sandwich mono/mono assays targeting N- and C-terminal epitopes to mitigate epitope masking.
-
Oligomeric IAPP: use conformation-specific capture; verify that the kit standard truly reflects the target species (oligomeric standard vs monomer).
-
High-insulin matrices: rigorous cross-reactivity documentation required; sandwich assays generally outperform competitive formats here.
Calibration, curve-fitting, and units
Calibrators
-
Use human-sequence synthetic IAPP for human studies; avoid mixed species.
-
Verify linearity over your expected range with dilutional parallelism (R² and slope close to 1.0 vs standard).
-
Replace standards upon visible turbidity or date/lot expiry.
Curve fitting
-
Fit with 5-parameter logistic (5-PL); if unavailable, 4-PL with 1/y² weighting to stabilize low-end variance.
-
Include duplicate standards and back-calculate to acceptance limits (e.g., ±15% at QC levels, ±20% at LLOQ).
Unit harmonization
-
Report ng/mL and pmol/L with MW ≈ 3.9 kDa.
-
Conversion: 1 ng/mL = (1×10⁻⁶ g/L) / (3900 g/mol) = 0.256 nM (≈ 256 pmol/L).
-
-
Publish the exact MW used, to avoid 5–10% drift due to differing MW assumptions.
Assay validation & on-plate QC
Precision & accuracy
-
Intra-assay %CV: ≤10% (good), ≤15% (acceptable).
-
Inter-assay %CV: ≤15% (good), ≤20% (acceptable).
-
Spike–recovery: 80–120% across low/mid/high spikes.
-
Dilution linearity: 80–120% over 1:2 to 1:16 dilutions.
Plate design
-
Randomize sample positions; avoid grouping by cohort or timepoint.
-
Use edge wells for standards/controls or leave empty to reduce edge effects.
-
Include two QC pools (low/high) on every plate for Levey–Jennings tracking.
Blanks and NSB
-
Run matrix blanks (matched serum/plasma stripped of IAPP if available).
-
Include no-antibody and no-antigen wells periodically to monitor nonspecific binding and reagent contamination.
Matrix effects & heterophilic antibody interference
-
Matrix effects: Compare sample-diluent vs calibrator diluent; if different, verify recovery and parallelism explicitly.
-
Heterophilic antibodies/RF: Use blocking reagents (e.g., mouse IgG, heterophilic blockers) if the antibody host species overlaps with common serum antibodies.
-
Lipemia/hemolysis/icterus: Document visually or spectrally; exclude or analyze separately if OD backgrounds exceed thresholds.
Handling IAPP’s amyloidogenicity
-
Work cold when possible; minimize dwell times in plastic.
-
Add carrier protein (0.1% BSA) or 0.05% Tween-20 if the kit allows.
-
Avoid repeated transfers; use wide-bore tips to reduce shear-induced aggregation.
-
If targeting monomeric IAPP, avoid strong detergents or chaotropes that may alter epitope presentation (unless validated).
Cross-kit and cross-study standardization
Internal normalization
-
Prepare study-specific pooled QC (large, well-mixed pool). Aliquot and freeze once; run on every plate.
-
Normalize each plate to the QC mean (plate factor) to reduce drift.
External reference material
-
If available, include a third-party reference (independent from kit calibrator).
-
Report sample results as a ratio to reference for meta-analysis compatibility.
Statistical harmonization
-
Use mixed-effects models with random effects for kit, lot, and plate.
-
For multi-batch omics-style harmonization, ComBat/empirical Bayes can reduce systematic shifts (after confirming assumptions).
-
Always re-run a subset (e.g., 10–15%) of samples across kits/lots to quantify bias and enable equation-based bridging (Deming regression).
Reporting minimums (a practical checklist)
-
Sample type (serum/EDTA/heparin/citrate; cell supernatant media).
-
Processing times (draw→spin, spin→freeze), temperatures, g-force.
-
Freeze–thaw count; storage time and temperature.
-
Kit brand/lot, antibody types (host, clone if known), format (sandwich/competitive), calibrator origin, curve model (4-PL/5-PL, weighting).
-
QC metrics (%CV, recovery, linearity), cross-reactivity tests performed, and unit conversion factor used.
Choosing the “right” kit for your use case (decision guide)
-
Clinical samples with high insulin: Prefer sandwich mono/mono, documented insulin/pramlintide cross-reactivity <1–2%.
-
Drug studies (pramlintide on-board): Require explicit pramlintide cross-reactivity testing; consider assay targeting unique IAPP epitopes absent in analog.
-
Mechanistic work on oligomers: Conformation-sensitive capture; verify calibrator mimics oligomeric state; report as “oligomeric IAPP equivalents.”
-
High-throughput screens: Favor kits with robust automation compatibility, stable low CVs at mid-range, and tolerant to small diluent differences.
Troubleshooting quick-reference
-
Low signal, good standards: Adsorption loss → add carrier/Tween; switch to low-bind plastics; shorten pre-incubation times.
-
Poor parallelism: Matrix effects or cross-reactivity → increase dilution, match diluents, add blockers, verify standard curve weighting.
-
High blanks/background: Heterophilic antibodies or plate coating issues → add heterophilic blockers; replace problematic reagent lot; check washer carryover.
-
Between-plate drift: Temperature or incubation timing inconsistencies → plate timers, calibrated shakers/incubators; apply QC-based normalization.
-
Non-reproducible spikes: Degraded standard or incorrect reconstitution → prepare fresh; verify pH/ionic strength; avoid vortexing that induces aggregation.
Example SOP fragments (ready to adapt)
Processing:
-
EDTA plasma tubes; invert 8–10×; on ice.
-
Spin 2000×g, 10 min, 4 °C ≤30 min from draw; aliquot 200 µL low-bind, snap-freeze at −80 °C.
-
Record times, temperatures, centrifuge ID.
Assay day:
-
Thaw once on ice; gentle mix; 1:2 in kit diluent + 0.05% Tween-20 (if validated).
-
Standards in duplicate; 5-PL with 1/y² weighting; back-calc acceptance ±15% (±20% at LLOQ).
-
Include QC-Low (~20–30% of mid-std) and QC-High (~70–80% of top std).
-
Reject plate if QC %CV >15% or QC means outside ±2 SD of Levey–Jennings.
Data reporting & sharing
-
Provide raw OD, fit parameters, back-calculated concentrations, and metadata (sample processing, kit/lot, curve model).
-
Share QC traces (Levey–Jennings) and bridging equations when combining datasets.
-
Report conversion factors and MW used for ng/mL ↔ pmol/L.
Key takeaways
-
Most variability originates before the assay: control matrix, time, temperature, and plastics.
-
Use two-epitope sandwich assays for total IAPP in complex matrices; document cross-reactivity with insulin/pramlintide/CGRP.
-
Standardize with pooled QC, plate randomization, rigorous curve fitting, and statistical harmonization across kits and lots.
-
Publish complete method metadata so other groups can reproduce and compare.
![AffiELISA® Bovine Islet amyloid polypeptide ELISA [ IAPP]](https://affigen.com/cdn/shop/files/5BAFG-E4345_5D_20AffiELISA_C2_AE_20Cattle_20IFNg_20Kit_20High-Resolution_20Interferon_20Gamma_20ELISA_20Detection_235aa63e-6cf8-4939-8762-b8b71a0189a4_535x.png?v=1712845741)

